Jubilant Life Sciences subsidiary, Jubilant Pharma has received the US FDA approval for Amantadine hydrochloride tablets- the generic version of Endo Pharma’s Symmetrel. continue reading…

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Register with your email to read the full article.

This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.



Astellas Buys Universal Cells in $102.5M Deal to Develop Universal Donor Cells

Japanese pharma company, Astellas acquired the US-based biotech firm, Universal Cells. Astellas will pay up to $102.5 million upfront plus milestones for the buyout. Continue reading..


Roche’s Blockbuster Drug Rituxan Prepares for New Rare Disease Treatment

Roche’s top-selling rheumatoid arthritis drug, Rituxan® (rituximab) received US FDA Priority Review status for the treatment of pemphigus vulgaris (PV), a rare, life-threatening condition that causes painful blistering of the skin and mucous membranes.


FDA Approves Glatopa, Generic Version of Teva’s Top-Selling Multiple Sclerosis Drug Copaxone

US FDA approved Glatopa®, generic version of Teva’s Copaxone developed by Sandoz (Novartis’ biosimilar division) in collaboration with Momenta Pharma. Continue reading...


FDA Approves Vertex Pharma’s Third Cystic Fibrosis Drug Symdeco

Vertex Pharma’s third cystic fibrosis drug, Symdeco™ received the US FDA approval for treating the underlying causes of cystic fibrosis in children aged 12 years and older, having two copies of the F508del mutation or one mutation that is responsive to Symdeco. Continue reading...

Most Popular


7 New Ideas to Start a Healthcare Business in India (2018)

Healthcare in India is showing a gradual progress and there is an abundance of opportunity to create an evolving business by tackling the major challenges of the mass population. Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our observations of the current Indian market, its behavior, challenges, and opportunities.


9 Most Valuable Drugs Under Development (2018)

The top 9 drugs currently under research and developments are ranked based on their Net Present Value. These drugs are forecasted to be the future blockbuster. With $10,199 million Net Present Value, Aducanumab, the Ant-Alzheimer's investigational drug of Biogen is ranked as the topmost valued upcoming drug under development. Total Word Counts of the article: 782. Continue reading..

Leave a reply